<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223742</url>
  </required_header>
  <id_info>
    <org_study_id>8-12-00 B</org_study_id>
    <nct_id>NCT01223742</nct_id>
  </id_info>
  <brief_title>Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy</brief_title>
  <official_title>ORAL ACETYL-L-CARNITINE THERAPY REDUCES FATIGUE IN HEPATIC ENCEPHALOPATHY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Catania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the effect of exogenous ALC on the both physical and&#xD;
      mental fatigue in mild and moderate encephalopatic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>December 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>ACETYL-L-CARNITINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ACETYL-L-CARNITINE</intervention_name>
    <description>2 g acetylcarnitine taken orally twice a day.</description>
    <arm_group_label>ACETYL-L-CARNITINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo twice per day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Chronic hepatitis with spontaneous manifest HE (mental state grade 1 or 2 according&#xD;
             to the West Haven criteria) and an NCT-A performance time &gt;30 seconds;&#xD;
&#xD;
          -  2) Hyperammonemia (venous ammonia concentration &gt;50 mmol/L);&#xD;
&#xD;
          -  3) Cooperative, hospitalised, adult patients with liver cirrhosis diagnosed by&#xD;
             clinical, histological and ultrasonographic findings (reduced dimensions of the liver&#xD;
             as well as splenomegaly) and oesophageal varices at stage II and III observed by&#xD;
             endoscopy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Major complications of portal hypertension, such as gastrointestinal blood loss,&#xD;
             hepatorenal syndrome or bacterial peritonitis;&#xD;
&#xD;
          -  2) Acute superimposed liver injury;&#xD;
&#xD;
          -  3) Patient with other neurological disease and metabolic disorders, diabetes mellitus,&#xD;
             unbalanced heart failure and/or respiratory failure or end-stage renal disease;&#xD;
&#xD;
          -  4) Alcoholic -toxic cirrhosis because toxic brain damage may interfere with the&#xD;
             assessment of HE;&#xD;
&#xD;
          -  5) Severe HE;&#xD;
&#xD;
          -  6) Administration of anti-HE medications such as neomycin, branched-chain amino acids;&#xD;
&#xD;
          -  7) Any additional precipitating factors such as high protein intake (additional&#xD;
             high-protein meals), constipation or intake of psycho stimulants, sedatives,&#xD;
             antidepressants, benzodiazepines, or benzodiazepines-antagonists (flumazenil),&#xD;
             beta-adrenergic blockers, neuromuscular blocking agents, certain antibiotics;&#xD;
&#xD;
          -  8) Patients with fever, sepsis or shock were also excluded to avoid variations caused&#xD;
             by body temperature;&#xD;
&#xD;
          -  9) Illiteracy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Cannizzaro Hospital</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2000</verification_date>
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

